Dual-receptor vs triple-receptor: how the leading approved incretin compares to the most-watched next-generation molecule, side by side.
Tirzepatide is the highest-efficacy incretin currently approved (Mounjaro / Zepbound); retatrutide is the leading investigational triple-agonist. Both target GIP and GLP-1 — retatrutide adds glucagon-receptor activity, which appears to drive its larger phase-2 weight-loss numbers. The phase-2 retatrutide NEJM paper and the SURMOUNT-1 tirzepatide trial are the canonical references for this comparison.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Class | Dual GIP / GLP-1 receptor agonist | Triple GIP / GLP-1 / glucagon receptor agonist |
| Receptors activated | 2 (GIP + GLP-1) | 3 (GIP + GLP-1 + glucagon) |
| FDA status | Approved (Mounjaro, Zepbound) | Investigational (Phase 3) |
| Dosing cadence | Once weekly | Once weekly |
| Half-life | ~5 days | ~6 days |
| Headline trial | SURMOUNT-1 (72 wk) | Phase 2 (NEJM, 48 wk) |
| Average weight reduction | ~20–22% at 72 wk | ~24% at 48 wk (phase-2) |
| Mechanistic differentiator | GIP + GLP-1 dual incretin effect | Adds glucagon-receptor activation, which increases energy expenditure |
| Common GI tolerability | Nausea, mild GI; dose-titrated | Comparable nausea profile in phase-2 data |
Tirzepatide is a synthetic peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The dual-incretin profile has drawn significant clinical and research interest.
By engaging GIP and GLP-1 receptors simultaneously, tirzepatide influences insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.
Retatrutide is a synthetic peptide engineered to activate three incretin/metabolic receptors at once — GLP-1, GIP, and glucagon. It is currently in late-stage clinical trials and represents the leading edge of next-generation metabolic peptide research.
Simultaneous agonism of GLP-1, GIP, and glucagon receptors combines incretin effects (insulin secretion, gastric emptying, appetite) with glucagon-driven energy expenditure.
Retatrutide's phase-2 numbers are the largest reported for any incretin-class molecule and exceed tirzepatide's approved-label efficacy, but it remains investigational pending phase-3 readouts. Tirzepatide is the highest-efficacy approved option today; any clinical decision should be made with a licensed practitioner.
The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Head-to-head clinical trials (SURPASS-2) suggest greater average weight reduction with tirzepatide, but individual response varies and any clinical decision should be made with a licensed provider.
Tirzepatide activates two receptors (GIP and GLP-1) on the same molecule, in contrast to semaglutide which targets only GLP-1.
Retatrutide activates three receptors (GLP-1, GIP, glucagon) versus semaglutide's one and tirzepatide's two. The added glucagon arm is thought to increase energy expenditure.
No — as of 2026 it is investigational and in late-stage trials.